Skip to main content
$50.10 $0.72 (1.5%)

04:00 PM EST on 12/01/23

Bristol-Myers Squibb Co. (NYSE:BMY)

CAPS Rating: 4 out of 5

Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments.

Current Price $50.10 Mkt Cap $101.9B
Open $49.40 P/E Ratio 12.71
Prev. Close $50.10 Div. (Yield) $2.28 (4.6%)
Daily Range $48.93 - $50.18 Volume 12,806,403
52-Wk Range $48.25 - $81.42 Avg. Daily Vol. 13,017,011

Caps

How do you think NYSE:BMY will perform against the market?

Add Stock to CAPS Watchlist

All Players

1,829 Outperform
115 Underperform
 

All-Star Players

274 Outperform
23 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NYSE:BMY Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Craigs22 (49.92)
Submitted October 04, 2021

Extremely attractive valuation for a company with a strong existing set of drugs and upside in their pipeline

msabol01 (81.63)
Submitted April 02, 2017

Strong pipeline and a culture that wants to innovate. Strong focus on patients. Leadership seems to struggle with launching products and being competitive out the door. Long term will either find BMY on strong footing or acquired.

Recent Community Commentary

Read the most recent pitches from players about BMY.

Recs

1
Member Avatar Craigs22 (49.92) Submitted: 10/4/2021 12:15:19 AM : Outperform Start Price: $55.62 NYSE:BMY Score: -16.02

Extremely attractive valuation for a company with a strong existing set of drugs and upside in their pipeline

Recs

1
Member Avatar asdfk123 (81.58) Submitted: 9/30/2021 12:32:58 PM : Outperform Start Price: $40.31 NYSE:BMY Score: -28.37

Added to position @$59.72 per share.

Recs

0
Member Avatar TMFkodyk123 (32.41) Submitted: 9/7/2021 7:32:03 PM : Outperform Start Price: $60.01 NYSE:BMY Score: -18.40

BMY's growth prospects are promising with anticoagulant blockbuster Eliquis and oncology blockbusters Revlimid and Opdivo. When combined with BMY's valuation, BMY is poised to beat the S&P 500 over the next 5-10 years.

Leaderboard

Find the members with the highest scoring picks in BMY.

Score Leader

d3lta4ce

d3lta4ce (33.64) Score: +255.45

The Score Leader is the player with the highest score across all their picks in BMY.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
3750399 50.48 2/17/2009 Underperform NS $12.84 +290.03% +482.88% +192.86 0 Comment
KlownKollegeGrad < 20 1/6/2012 Underperform 1Y $23.88 +109.62% +258.76% +149.14 0 Comment
GuruMF3 67.99 6/27/2016 Underperform 5Y $55.95 -10.51% +130.09% +140.60 0 Comment
Biotechnut < 20 7/9/2012 Underperform 5Y $24.56 +103.86% +239.12% +135.26 0 Comment
GuruMF6 64.18 5/10/2016 Underperform 5Y $56.90 -12.01% +122.09% +134.10 0 Comment
GuruMF5 62.54 5/10/2016 Underperform 5Y $56.90 -12.01% +122.09% +134.10 0 Comment
GuruMF4 30.94 6/13/2016 Underperform 3W $57.34 -12.69% +119.82% +132.51 0 Comment
imobillc < 20 8/29/2011 Underperform 5Y $20.03 +149.91% +282.20% +132.29 0 Comment
GrandeTeam 25.63 11/16/2011 Underperform 5Y $21.56 +132.16% +263.99% +131.83 0 Comment
bclan13 64.56 9/30/2013 Underperform 5Y $33.77 +48.23% +174.12% +125.89 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BMY.